|Table of Contents|

The effect and mechanism of CDK1 gene on proliferation and migration of hepatocellular carcinoma HepG2 and Huh7 cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 16
Page:
2990-2998
Research Field:
Publishing date:

Info

Title:
The effect and mechanism of CDK1 gene on proliferation and migration of hepatocellular carcinoma HepG2 and Huh7 cells
Author(s):
YANG Ying; ZHANG Qimin; GUO Yufan; LI Huixin; ZHANG Shunbo; SUN Yu
Fenyang College of Shanxi Medical University,Shanxi Fenyang 032200,China.
Keywords:
CDK1; hepatocellular carcinoma; proliferation; migration
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2024.16.010
Abstract:
Objective:To explore the correlation between CDK1 expression and prognosis and clinical features of hepatocellular carcinoma based on bioinformatics analysis,and further explored its effect on the proliferation and migration of hepatocellular carcinoma cells HepG2 and Huh7 by experiment.Methods:The differences in the expression of CDK1 gene in hepatocellular carcinoma and normal liver tissues were analyzed by searching TIMER database and GEPIA database.The expression level of CDK1 protein in hepatocellular carcinoma was verified with the help of UALCAN database,and the expression of CDK1 in GSE45267 and GSE121247 datasets was analyzed by using R software,and the relationship between CDK1 and clinicopathological parameters of hepatocellular carcinoma as well as the prognostic value were analyzed by using single-factor and multifactor regression,and the relationship between CDK1 expression and survival rate of hepatocellular carcinoma patients was analyzed by using GEPIA and Kaplan-Meier Plotter database.Hepatocellular carcinoma cells HepG2 and Huh7 were divided into control group and si_CDK1 group (cells transfected with CDK1-inhibitor),cell proliferation rate was detected by CCK-8 assay,cell healing rate was detected by cell scratch assay,and Transwell migration assay was analyzed to calculate the number of cell migration.Positive and negative genes co-expressed with CDK1 were explored by LinkedOmics database,and pathway enrichment analysis was performed.Western blot was used to detect cell cycle and apoptosis related protein expression in each group of cells.Results:The expression of CDK1 in hepatocellular carcinoma was significantly higher than that in normal liver tissues,and CDK1 was an independent risk factor affecting hepatocellular carcinoma patients,and the higher the expression of CDK1,the worse the survival and prognosis of the patients.CDK1 co-expressed genes were mainly involved in the cell cycle,DNA replication,etc.Compared with the Control group,the proliferation,healing rate,and migratory ability of hepatocellular carcinoma cells in the si_CDK1 group were obviously reduced,and the expression of the cell cycle protein CyclinD1,and apoptotic pathway Bcl-2 were significantly reduced.Conclusion:CDK1 expression is significantly elevated in hepatocellular carcinoma tissues and correlates with poor patient prognosis.Silencing CDK1 can cause a significant decrease in the proliferation and migration of hepatocellular carcinoma cells,cause cell cycle arrest,and promote apoptosis.

References:

［1］ GANESAN P,KULIK LM.Hepatocellular carcinoma:new developments［J］.Clin Liver Dis,2023,27(1):85-102.
［2］ WEN N,CAI Y,LI F,et al.The clinical management of hepatocellular carcinoma worldwide:A concise review and comparison of current guidelines:2022 update［J］.Biosci Trends,2022,16(1):20-30.
［3］ CLARK T,MAXIMIN S,MEIER J,et al.Hepatocellular carcinoma:review of epidemiology,screening,imaging diagnosis,response assessment,and treatment［J］.Curr Probl Diagn Radiol,2015,44(6):479-486.
［4］ HELLER M,PARIKH ND,FIDELMAN N,et al.Frontiers of therapy for hepatocellular carcinoma［J］.Abdom Radiol (NY),2021,46(8):3648-3659.
［5］ LI JI，STAGG NJ，JOHNSTON J，et al.Membrane-Proximal epitope facilitates efficient T cell synapse formation by Anti-FcＲH5/CD3 and is a requirement for myeloma cell killing［J］.Cancer Cell,2017,31(3):383-395.
［6］ SUNADA S,SAITO H,ZHANG D,et al.CDK1 inhibitor controls G2/M phase transition and reverses DNA damage sensitivity［J］.Biochem Biophys Res Commun,2021,550:56-61.
［7］ EL DIKA M,DUDKA D,KLOC M,et al.CDC6 as a key inhibitory regulator of CDK1 activation dynamics and the timing of mitotic entry and progression［J］.Biology (Basel),2023,12(6):855.
［8］ MOCH H,CUBILLA AL,HUMPHREY PA,et al.The 2016 WHO classification of tumous of the urinary system and male genital organs-Part A:renal，penile，and testicular tumous ［J］.Eur Urol,2016,70(1):93－105.
［9］ SHAO Z,LI C,WU Q,et al.ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1［J］.Oncogenesis,2022,11(1):44.
［10］ QU X,YU B,ZHU M,et al.Sinomenine inhibits the growth of ovarian cancer cells through the suppression of mitosis by down-regulating the expression and the activity of CDK1［J］.Onco Targets Ther,2021,14:823-834.
［11］ TONG Y,HUANG Y,ZHANG Y,et al.DPP3/CDK1 contributes to the progression of colorectal cancer through regulating cell proliferation,cell apoptosis,and cell migration［J］.Cell Death Dis,2021,12(6):529.
［12］ HE J,GAO R,YANG J,et al.NCAPD2 promotes breast cancer progression through E2F1 transcriptional regulation of CDK1［J］.Cancer Sci,2023,114(3):896-907.
［13］ HARTKE J,JOHNSON M,GHABRIL M.The diagnosis and treatment of hepatocellular carcinoma［J］.Semin Diagn Pathol,2017,34(2):153-159.
［14］ SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71(3):209-249.
［15］ 翟来慧,陆海波.晚期原发性肝细胞癌的药物治疗［J］.现代肿瘤医学，2020,28(02):326-329. ZHAI Laihui,LU Haibo.Drug therapy of advanced primary hepatocellular carcinoma［J］.Modern Oncology,2020,28(02):326-329.

Memo

Memo:
山西省高等学校科技创新项目(编号：2022L673）；山西医科大学汾阳学院校级项目（编号：2022C20）
Last Update: 1900-01-01